Business Context and Reporting Period
Company: Allogene Therapeutics, Inc. (ALLO)
Filing Type: Form 8-K (Current Report)
Date of Report: August 1, 2025
Subject: Modification of the ALPHA3 clinical study design for cemacabtagene ansegedleucel (cema-cel) in large B-cell lymphoma (LBCL).
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a clinical trial event and does not contain financial statements. The document does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Events
- Regimen Change: The Company selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen for the ALPHA3 study, following consultation with the FDA, DSMB, and Steering Committee.
- Arm Closure: The arm testing FC plus ALLO-647 (an anti-CD52 mAb) is closed to further enrollment.
- Adverse Event: The decision was prompted by a Grade 5 adverse event (death) in the FC plus ALLO-647 arm due to hepatic failure from a disseminated adenovirus infection. The event occurred on Day 54 post-infusion and was attributed to immune suppression caused by ALLO-647, not cema-cel.
- Strategic Shift: ALLO-647 is removed from all open trials and pipeline programs. Future AlloCAR T candidates will utilize the proprietary Dagger Platform Technology to minimize or eliminate the need for standard lymphodepletion.
- Study Design Update: The amended ALPHA3 trial is now a randomized study comparing cema-cel after standard FC lymphodepletion to observation (standard of care).
Guidance, Outlook, and Risks
- Next Milestone: A futility analysis comparing minimal residual disease (MRD) conversion is expected in the first half of 2026.
- Operational Status: Over 50 clinical sites are activated across the United States and Canada.
- Risks: Forward-looking statements are subject to risks including novel technology unpredictability, potential side effects, FDA regulatory disagreements, patient enrollment difficulties, and manufacturing challenges.
Investor Verification Checklist
- Verify the specific details of the Grade 5 adverse event and the FDA's stance on the regimen change.
- Confirm the timeline for the futility analysis (expected H1 2026) and potential impact on capital requirements.
- Assess the development status and regulatory pathway of the Dagger Platform Technology as a replacement for ALLO-647.
- Review the Company's cash runway in light of the trial modification and potential delays.